Kineta Awarded NIH/NIAID Contract to Develop New Therapies for Viral Diseases
SEATTLE, WA July 29, 2015 – Kineta, Inc., a biotechnology company focused on the development of immune modulating drugs for critical diseases, today announced it has been awarded a new National Institute of Allergy and Infectious Diseases (NIAID)* contract for $1.4 M for the base period, with options to exercise an additional $2.52 M over two to three years to develop its broad-spectrum antiviral therapeutics to address a variety of viral diseases.
Read more ›
Washington Global Health Alliance announces 2015 Pioneers of Global Health Award winners
WGHA is pleased to announce the 2015 Pioneers of Global Health Award winners. This year’s winners, selected by a panel of global health experts, are noted for their significant achievements in monitoring and evaluation, reproductive health and formulating vaccine adjuvants for disease like malaria and tuberculosis. Read more ›